Investing

Top Analyst Upgrades and Downgrades: Autodesk, IBM, Lumber Liquidators, NVIDIA, Salesforce, Symantec, T-Mobile, Wal-Mart and More

Applied Materials Inc. (NASDAQ: AMAT) was up 2.7% at $43.91 on Thursday and was indicated up 2.6% more at $45.05 on Friday after earnings. Cowen has an Outperform rating and raised its target to $50 from $45. Stifel has a Buy rating and raised its target to $55 from $50.

Athenahealth Inc. (NASDAQ: ATHN) was reiterated as Outperform and the price target was raised to $154 from $119 at Oppenheimer. Jefferies raised its Hold rating and raised its price target to $135 from $95.

AxoGen Inc. (NASDAQ: AXGN) was reiterated as Outperform and the price target was raised to $17 from $14 (versus a $13.90 prior close) at Wedbush.

Cullen/Frost Bankers Inc. (NYSE: CFR) was raised to Neutral from Underperform with a $92 price target at Wedbush. While the firm feels that Cullen/Frost would benefit from the Trump tailwinds, the firm feels its earnings should benefit less than other banks.

Extraction Oil & Gas LLC (NASDAQ: XOG) was started as Market Perform with a $19 price target at BMO Capital Markets.

First Data Corp. (NYSE: FDC) was started as Outperform at Raymond James.

Palo Alto Networks Inc. (NYSE: PANW) was raised to Buy and the price target was raised to $150 from $130 at Jefferies. The firm believes that Palo Alto Networks recent operational weakness has more to do with a major product cycle than sales execution or increased competitive issues and should be followed by a reacceleration of the business over the next quarters.

Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) was started with a Strong Buy rating and assigned a $36 price target at Raymond James. Paratek was down 0.7% at $21.40 on Thursday but was indicated up 7% at $22.94 on Friday.

Prosperity Bancshares Inc. (NASDAQ: PB) was raised to Neutral from Underperform and the $67 price target was maintained at Wedbush. While Wedbush’s fundamental view on Prosperity has not changed, the firm believes its concerns are more properly reflected in the current valuation.

Thermo Fisher Scientific Inc. (NYSE: TMO) was started as Overweight with a $194 price target (versus a $171.74 prior close) at Cantor Fitzgerald.

Vital Therapies Inc. (NASDAQ: VTL) was started with an Outperform rating and assigned a $6 price target at Raymond James. Vital Therapies closed down 8.7% at $2.60 on Thursday, and this company has a mere $109 million market cap.

Thursday’s top analyst and downgrades were in Cisco Systems, Expedia, Exxon Mobil, First Solar, Noble, Shake Shack, Symantec and over a dozen more.